MS Learn Online is the National MS Society’s online educational webcast series. This video features a discussion with Nicholas LaRocca, PhD, who talks occupational therapy for a person with multiple sclerosis.
Video Rating: 0 / 5
Article by hi joiney
HistoryPhysicians like Hippocrates and later Galenus are believed to have been the first practitioners of physical therapy, advocating massage, manual therapy techniques and hydrotherapy to treat people in 460 B.C.[verification needed] After the development of orthopedics in the eighteenth century, machines like the Gymnasticon were developed to treat gout and similar diseases by systematic exercise of the joints, similar to later developments in physical therapy.The earliest documented origins of actual physical therapy as a professional group date back to Per Henrik Ling ather of Swedish Gymnastics who founded the Royal Central Institute of Gymnastics (RCIG) in 1813 for massage, manipulation, and exercise. The Swedish word for physical therapist is jukgymnast = ick-gymnast. In 1887, PTs were given official registration by Sweden National Board of Health and Welfare.Other countries soon followed. In 1894 four nurses in Great Britain formed the Chartered Society of Physiotherapy. The School of Physiotherapy at the University of Otago in New Zealand in 1913, and the United States’ 1914 Reed College in Portland, Oregon, which graduated “reconstruction aides.”Research catalyzed the physical therapy movement. The first physical therapy research was published in the United States in March 1921 in The PT Review. In the same year, Mary McMillan organized the Physical Therapy Association (now called the American Physical Therapy Association (APTA). In 1924, the Georgia Warm Springs Foundation promoted the field by touting physical therapy as a treatment for polio.Treatment through the 1940s primarily consisted of exercise, massage, and traction. Manipulative procedures to the spine and extremity joints began to be practiced, especially in the British Commonwealth countries, in the early 1950s. Later that decade, physical therapists started to move beyond hospital based practice, to outpatient orthopedic clinics, public schools, college/universities, geriatric settings (skilled nursing facilities), rehabilitation centers, hospitals, and medical centers.Specialization for physical therapy in the U.S. occurred in 1974, with the Orthopaedic Section of the APTA being formed for those physical therapists specializing in orthopaedics. In the same year, the International Federation of Orthopaedic Manipulative Therapy was formed, which has played an important role in advancing manual therapy worldwide ever since. EducationMain article: List of physical therapy trainingWorld Confederation of Physical Therapy (WCPT) recognises there is considerable diversity in the social, economic, cultural, and political environments in which physical therapist education is conducted throughout the world. WCPT recommends physical therapist entry-level educational programs be based on university or university-level studies, of a minimum of four years, independently validated and accredited as being at a standard that accords graduates full statutory and professional recognition. WCPT acknowledges there is innovation and variation in program delivery and in entry-level qualifications, including first university degrees (Bachelors/Baccalaureate/Licensed or equivalent), Masters and Doctorate entry qualifications. What is expected is that any program should deliver a curriculum that will enable physical therapists to attain the knowledge, skills, and attributes described in these guidelines.Professional education prepares physical therapists to be autonomous practitioners in collaboration with other members of the health care team.Physical therapist entry-level educational programs integrate theory, evidence and practice along a continuum of learning. This begins with admission to an accredited physical therapy program and ending with retirement from active practice.202 of 211 accredited physical therapy programs in the US are accredited at the doctoral level. Specialty areasBecause the body of knowledge of physical therapy is quite large, some PTs specialize in a specific clinical area. While there are many different types of physical therapy, the American Board of Physical Therapy Specialties list seven specialist certifications, including Sports Physical Therapy and Clinical Electrophysiology. Worldwide the six most common specialty areas in physical therapy are: CardiopulmonaryCardiovascular and pulmonary rehabilitation physical therapists treat a wide variety of individuals with cardiopulmonary disorders or those who have had cardiac or pulmonary surgery. Primary goals of this specialty include increasing endurance and functional independence. Manual therapy is used in this field to assist in clearing lung secretions experienced with cystic fibrosis. Disorders, including heart attacks, post coronary bypass surgery, chronic obstructive pulmonary disease, and pulmonary fibrosis, treatments can benefit[citation needed] from cardiovascular and pulmonary specialized physical therapists.[verification needed] GeriatricGeriatric physical therapy covers a wide area of issues concerning people as they go through normal adult aging but is usually focused on the older adult. There are many conditions that affect many people as they grow older and include but are not limited to the following: arthritis, osteoporosis, cancer, Alzheimer’s disease, hip and joint replacement, balance disorders, incontinence, etc.Geriatric physical therapy helps[citation needed] those affected by such problems in developing a specialized program to help restore mobility, reduce pain, and increase fitness levels.[verification needed] NeurologicalNeurological physical therapy is a discipline focused on working with individuals who have a neurological disorder or disease. These include Alzheimer’s disease, Charcot-Marie-Tooth disease (CMT), ALS, brain injury, cerebral palsy, multiple sclerosis, Parkinson’s disease, spinal cord injury, and stroke. Common impairments associated with neurologic conditions include impairments of vision, balance, ambulation, activities of daily living, movement, speech and loss of functional independence. OrthopaedicOrthopaedic physical therapists diagnose, manage, and treat disorders and injuries of the musculoskeletal system including rehabilitation after orthopaedic surgery. This specialty of physical therapy is most often found in the out-patient clinical setting. Orthopaedic therapists are trained in the treatment of post-operative orthopaedic procedures, fractures, acute sports injuries, arthritis, sprains, strains, back and neck pain, spinal conditions and amputations.Joint and spine mobilization/manipulation, therapeutic exercise, neuromuscular reeducation, hot/cold packs, and electrical muscle stimulation (e.g., cryotherapy, iontophoresis, electrotherapy) are modalities often used to expedite recovery in the orthopaedic setting.[verification needed] Additionally, an emerging adjunct to diagnosis and treatment is the use of sonography for diagnosis and to guide treatments such as muscle retraining. Those who have suffered injury or disease affecting the muscles, bones, ligaments, or tendons of the body will benefit[citation needed] from assessment by a physical therapist specialized in orthopaedics. PediatricPediatric physical therapy assists in early detection of health problems and uses a wide variety of modalities to treat disorders in the pediatric population. These therapists are specialized in the diagnosis, treatment, and management of infants, children, and adolescents with a variety of congenital, developmental, neuromuscular, skeletal, or acquired disorders/diseases. Treatments focus on improving gross and fine motor skills, balance and coordination, strength and endurance as well as cognitive and sensory processing/integration. Children with developmental delays, cerebral palsy, spina bifida, or torticollis, may be treated[citation needed] by pediatric physical therapists.[verification needed] IntegumentaryIntegumentary (treatment of conditions involving the skin and related organs). Common conditions managed include wounds and burns. Physical therapists utilize surgical instruments, mechanical lavage, dressings and topical agents to debride necrotic tissue and promote tissue healing. Other commonly used interventions include exercise, edema control, splinting, and compression garments. See alsoJoint manipulationManual handlingOccupational TherapyPhysical medicine and rehabilitation References^ Description of Physical Therapy – The World Confederation for Physical Therapy (WCPT)^ American Physical Therapy Association. “Discovering Physical Therapy. What is physical therapy”. American Physical Therapy Association. http://www.apta.org/AM/Template.cfm?Section=Consumers1&Template=/CM/HTMLDisplay.cfm&ContentID=39568. Retrieved 2008-05-29. ^ American Physical Therapy Association Section on Clinical Electrophysiology and Wound Management. “Curriculum Content Guidelines for Electrophysiologic Evaluation” (PDF). Educational Guidelines. American Physical Therapy Association. http://www.aptasce-wm.org/documents/guidelines/ENMG%20EvaluationGuidelines.pdf. Retrieved 2008-05-29. ^ American Physical Therapy Association (2008-01-17). “APTA Background Sheet 2008″. American Physical Therapy Association. http://www.apta.org/AM/Template.cfm?Section=Physical_Therapy&TEMPLATE=/CM/HTMLDisplay.cfm&CONTENTID=33205. Retrieved 2008-05-29. ^ Wharton MA. Health Care Systems I; Slippery Rock University. 1991^ Sarah Bakewell, “Illustrations from the Wellcome Institute Library: Medical Gymnastics and the Cyriax Collection,” Medical History 41 (1997), 487-495.^ Chartered Society of Physiotherapy (n.d.). “History of the Chartered Society of Physiotherapy”. Chartered Society of Physiotherapy. http://www.csp.org.uk/director/about/thecsp/history.cfm. Retrieved 2008-05-29. ^ Knox, Bruce (2007-01-29). “History of the School of Physiotherapy”. School of Physiotherapy Centre for Physiotherapy Research. University of Otago. http://physio.otago.ac.nz/about/history.asp. Retrieved 2008-05-29. ^ Reed College (n.d.). “Mission and History”. About Reed. Reed College. http://www.reed.edu/about_reed/history.html. Retrieved 2008-05-29. ^ Roosevelt Warm Springs Institute (n.d.). “History”. About Us. Roosevelt Warm Springs Institute. http://www.rooseveltrehab.org/history.php. Retrieved 2008-05-29. ^ McKenzie, R A (1998). The cervical and thoracic spine: mechanical diagnosis and therapy. New Zealand: Spinal Publications Ltd.. pp. 1620. ISBN 978-0959774672. ^ McKenzie, R (2002). “Patient Heal Thyself”. Worldwide Spine & Rehabilitation 2 (1): 1620. ^ Lando, Agneta (2003). “History of IFOMT”. International Federation Orthopaedic Manipulative Therapists (IFOMT). http://www.ifomt.org/ifomt/about/history. Retrieved 2008-05-29. ^ American Physical Therapy Association (n.d.). “APTA Sections”. American Physical Therapy Association. http://www.apta.org/AM/Template.cfm?Section=Chapters&Template=/CM/ContentDisplay.cfm&CONTENTID=36890. Retrieved 2008-05-29. ^ ^ a b c d e Inverarity, Laura; Grossman, K (2007-11-28). “Types of Physical Therapy”. About.com. The New York Times Company. http://physicaltherapy.about.com/od/typesofphysicaltherapy/a/typesofpt.htm. Retrieved 2008-05-29. ^ Cameron, Michelle H. (2003). Physical agents in rehabilitation: from research to practice. Philadelphia: W. B. Saunders. ISBN 0-7216-9378-4. ^ Bunce SM, Moore AP, Hough AD (May 2002). “M-mode ultrasound: a reliable measure of transversus abdominis thickness?”. Clin Biomech (Bristol, Avon) 17 (4): 3157. doi:10.1016/S0268-0033(02)00011-6. PMID 12034127. http://linkinghub.elsevier.com/retrieve/pii/S0268003302000116. ^ Wallwork TL, Hides JA, Stanton WR (October 2007). “Intrarater and interrater reliability of assessment of lumbar multifidus muscle thickness using rehabilitative ultrasound imaging”. J Orthop Sports Phys Ther 37 (10): 60812. PMID 17970407. ^ Henry SM, Westervelt KC (June 2005). “The use of real-time ultrasound feedback in teaching abdominal hollowing exercises to healthy subjects”. J Orthop Sports Phys Ther 35 (6): 33845. PMID 16001905. Find more about Physical therapy on Wikipedia’s sister projects: Definitions from Wiktionary Textbooks from Wikibooks Quotations from Wikiquote Source texts from Wikisource Images and media from Commons News stories from Wikinews Learning resources from Wikiversityv d eAllied health professionsAthletic training Audiology Chiropractic Dental hygiene Dietetics Electrocardiographic technicians Emergency medical services Hemodialysis technicians Massage therapy Medical assistants Medical physics Medical technologist Medical transcription Music therapy Nuclear medicine technology Nutrition Occupational therapy Optometry Pharmacy Phlebotomy Orthotics/Prosthetics Physical therapy Psychology Public health Radiation therapy Radiography Radiologic technologist Respiratory therapy Social work Speech and language pathology Ultrasonography Categories: Health sciences | Rehabilitation medicine | Healthcare occupations | Physical therapy | Sports medicine | Therapy | Exercise | Manipulative therapy | Massage | Hospital departments | Allied Health ProfessionsHidden categories: All pages needing factual verification | Wikipedia articles needing factual verification from May 2008 | All articles with unsourced statements | Articles with unsourced statements from January 2010 | Wikipedia articles needing factual verification from January 2010
About the Author
I am a professional writer from China Crafts Suppliers, which contains a great deal of information about double ended dildo, realistic blow up doll, welcome to visit!
Stem cell therapy enables legendary Ennis, Texas football coach to see his son in Super Bowl XLV
Article by Free Eboooks
In a special to CNN, the Mayo Clinic’s mayoclinic.com reported that, “Parkinson’s disease is progressive, meaning the signs and symptoms become worse over time. But although Parkinson’s may eventually be disabling, the disease often progresses gradually, and most people have many years of productive living after a diagnosis.” This would indicate that there may be effective interventions that could perhaps slow the progress of the disease. When we get such a diagnosis, our first reaction might be to withdraw and give up. However, the old adage “use it or lose it” tells us that just the opposite is true. If you have Parkinson’s, you’d likely be best off to use everything your body is, every which way, on a regular basis.
Tai Chi movement’s gentle balance enhancing motions can obviously help the Parkinson’s patient by helping to reduce the gradual loss of balance that Parkinson’s sufferers often experience. However, there may be much more it offers. For example, Tai Chi movements rotate the human body in about 95% of the ways the body can move, when a long form is practiced. This is far beyond what other exercise offers, and in fact the closest would be several swimming strokes, which together would only rotate the body in about 65% of the ways it can move. For Parkinson’s sufferers, or anyone for that matter, this would indicate that by “using” 95% of the body’s possible motion several times a week, the possibility of “losing” the ability to do so diminishes accordingly. This isn’t rocket science, but simple common sense.
Yet, perhaps Parkinson’s patients have even more to gain from Tai Chi. A few years ago I taught several classes at local medical centers. I was continually frustrated because although I’d seen emerging reports that Tai Chi was beneficial to people with Parkinson’s Disease, or arthritis, or chronic hypertension, etc., even though the departments that specialized in those conditions were often just down the hall from my Tai Chi class . . . they might as well have been a million miles away. Because the physicians who ran those departments were either ignorant of or unwilling to refer their patients to the possibilities that Tai Chi offered their lives.
I remember though, that at one medical center a visionary neurologist began to refer patients with balance disorders to my Tai Chi classes and the result was very beneficial for his patients. Another physician actually wrote prescriptions for my Tai Chi classes to treat the chronic hypertension of his patients, who’d seen a significant drop in their blood pressure since beginning the classes weeks before. A clinical psychologist brought me in to teach Qigong (Chi Kung) meditation and Tai Chi to her patient group to enhance their sense of well being and provide effective stress management training. So, even back then some physicians were seeing the potential Tai Chi offered their clients, and even more are now, but the number of physicians who are still not informing their patients of Tai Chi’s direct therapeutic or at the least adjunct therapy benefits to their patient’s efforts to deal with their conditions and life, is increasingly indefensible in this day and age. Given the research that has exposed the many physical, mental, and emotional benefits Tai Chi offers, for physicians to not educate themselves on this and share their knowledge with each and every patient is tantamount to mal-practice. Health educators should likewise be making such therapies part of their medical student education programs as well.
Tai Chi for Parkinson’s is being recommended increasingly by support groups and some progressive medical centers, but until everyone that has Parkinson’s knows about it, then our work at World Tai Chi & Qigong Day is not done, nor is the medical community’s. There are many obvious reasons everyone with Parkinson’s should be doing Tai Chi, but it’s the ones that are not yet obvious that may be the most intriguing. One obvious reason is that Tai Chi is the most powerful balance and coordination enhancing exercise known. In many studies at major universities Tai Chi was found to be TWICE as effective in reducing falls as the other balance enhancing exercises being studied. For people with Parkinson’s, who often see their balance deteriorate as their condition progresses, it is unforgivable for them to not be informed of Tai Chi’s potential benefits at the earliest stage possible while their balance is still good.
Now, regarding the less obvious reasons Tai Chi may benefit Parkinson’s patients. Both my wife and daughter, who co-taught a Tai Chi class together noticed that a young man with severe Parkinson’s tremors . . . completely lost his tremors once he joined the class in flowing through the Tai Chi movements in class. In another class I was teaching an older man with advanced Parkinson’s attended my classes for many months, and he always came in very slow with his walker. Once we began the Tai Chi movements he no longer used his walker, and had learned the entire long form of Tai Chi I taught, which was over 15 minutes of continuous changing forms. His form was unique and tailored for his limitations, but nonetheless a challenging set of exercises he was able to accomplish without the use of his walker. What do these anecdotal experiences portend for others with Parkinson’s? I don’t know, but there should be massive research dollars coming from the National Institutes of Health to find out. Given the promise Tai Chi seems to offer people on so many profound physical, emotional, and mental fronts from preliminary research, the current total research money earmarked for complimentary and alternative medicine’s (CAM) is a mere pittance.
The National Center for Complementary and Alternative Medicine (NCCAM), now in its sixth year, supports more than 300 research projects and has an estimated budget of over 0 million for 2005 (up from million in 1999). Total spending on CAM by all NIH institutes and centers is expanding as well, and is expected to reach 5 million by 2005.
Sounds like a lot? However, 0 million is less than “one half of one percent” of the total NIH FY2005 budget. According to the Association of American Medical Colleges the NIH’s total annual budget for FY 2005 is .8 billion. Remember, we are talking about only spending much much less than one half of one percent to study an exercise that preliminary research has shown to: n Lower High Blood Pressure (about 1/3 of Americans have hypertension – roughly over 90 million Americans) n Boost Immune Function profoundly (a study sited at drkoop.com indicates that a Tai Chi practicing group was TWICE as resistant to the shingles virus, and researchers believed this would carry over to other viral resistance as well.) n Dramatically reduce falling injuries by about half (complications from falling injuries in older Americans is the 6th leading cause of death for seniors in America)
If Tai Chi only addressed this chronic condition affecting 1/3 of Americans, while boosting the immune system of all practitioners profoundly, and cutting in half the sixth leading cause of death for seniors, without any negative side effects, that would seem to be, for the rational person a reason for pouring massive resources into researching it further. However, Tai Chi’s benefits only begin with the above preliminary findings. We also know that it may very well relieve depression, anxiety, and mood disturbance, as well as reduce ADHD symptoms in teenagers diagnosed with Attention Deficit and Hyperactivity Disorder. There are indications that Tai Chi may greatly reduce or even eliminate chronic pain conditions, and lessen allergic and asthmatic reactions, and improve overall respiratory function.
My point is, “where is the massive attention this would garner on talk shows, and in health newspaper sections, if this were a drug or surgery that could provide such a seemingly massive breakthrough in health treatment?” Peter Chowka, in a brilliant two part series for Natural Health Line, entitled “Complementary & Alternative Medicine in 2000,” wrote, “Conflicts of interest are not uncommon in most aspects of life. But in medicine, the biggest business in the U.S. (over .5 trillion a year constituting over 14 percent of the Gross Domestic Product, according to the National Academy of Science’s Institute of Medicine report issued January 10, 2001), serious conflicts are particularly well entrenched.” Mr. Chowka wrote of physicians like Dr. Marcia Angell voicing concerns of the “troubling” result massive research money from drug and medical-equipment companies was having on the scientific process. In the New England Journal of Medicine’s May 18, 2000 issue, Dr. Angel wrote an editorial entitled, “Is Academic Medicine for Sale?” She wrote, “As we spoke with research psychiatrists about writing an editorial on the treatment of depression . . . we found very few who did not have financial ties to drug companies that make antidepressants. . .The problem is by no means unique to psychiatry. We routinely encounter similar difficulties in finding editorialists in other specialties, particularly those that involve the heavy use of expensive drugs and devices.”
So, who can make a multi-billion dollar fortune teaching Tai Chi to people? No one can. Tai Chi cannot be bottled, or mass marketed. It is a decentralized labor intensive industry that employees many people, but keeps the profits small and local. Yes, there are videos and DVDs that teach Tai Chi effectively, but ultimately even those who utilize videos are drawn to live class like structures. As I mentioned before with the “anecdotal” experiences of my students with Parkinson’s, Tai Chi seems to offer something profoundly beneficial to the quality of life of Parkinson’s sufferers. It needs further study. We are in a catch 22, where many health professionals feel they cannot recommend Tai Chi because too much of the preliminary research is anecdotal. However, when Tai Chi is jockeying for position to get a crumb of the .5% of total NIH money going to ALL complimentary and alternative medical therapies . . . the result will be many long years of millions of people suffering needlessly from conditions or symptoms of those conditions that Tai Chi could likely safely lessen or even eliminate.
WHAT DO WE KNOW ABOUT TAI CHI AND PARKINSONS?
Tai Chi is being recommended by some forward thinking medical institutions already. The Cleveland Clinic of Neuroscience Center encourages Parkinson’s Disease patients to seek out a hobby or activity they can enjoy and stick with such as “Tai Chi” and other activities. The Alexian Neurosciences Institute in Illinois offers a course in their The Parkinson’s Disease and Movement Disorders Center. Also, the American Parkinson’s Disease Association at Stanford University Medical Center, in it’s “Beyond Pills…. Alternative Approaches to Coping with Parkinson’s Disease” program, offered “Tai Chi, The Art for Living with Parkinson’s” by Mwezo & Jane of Kujiweza Healing Art. The Parkinson’s Society of Canada recommends Tai Chi for Parkinson’s patients, suggesting “Tai Chi may prevent or at least slow down the onset of degenerative diseases; in the long run, it can reduce need for rehabilitative care.” In the United Kingdom a Parkinson’s Tai Chi study was conducted at Camborne Redruth Community Hospital, Cornwall. Their conclusion of the study was such, “Tai Chi training was well tolerated by PD patients in this study, but had no measurable effect on motor performance using UPDRS score or GAG time. There was a non-significant improvement in quality of life scores (PDQ 39). Larger studies would be needed fully to evaluate the value and efficacy of Tai Chi. However our results are encouraging, and provide evidence for its safety and tolerability and would support the feasibility of further study.” WCHS TV during a news report focusing on Tai Chi’s ability to boost immune system function, also reported that “Tai Chi has also been shown to help illnesses such as Parkinson’s disease, multiple sclerosis, fibromyalgia and arthritis.” The Neurology Channel reported, “The slow flowing movements of Tai Chi help maintain flexibility, balance, and relaxation. The Struthers Parkinson’s Center in Minneapolis, which teaches a modified form of Tai Chi, consistently reports benefits achieved by patients in all stages of Parkinson’s.” Physicians at the Mayo Clinic recommend Tai Chi for Parkinson’s therapy, under their Parkinson’s “self-care” section for avoiding falls, where they suggest you “Ask your doctor or physical therapist about exercises that improve balance, especially tai chi. Originally developed in China more than 1,000 years ago, tai chi uses slow, graceful movements to relax and strengthen muscles and joints. “
At a popular health website called “RemedyFind.com” viewers can vote on therapies they’ve found benefited their condition, or didn’t benefit it. The rating there for Tai Chi as a Parkinson’s therapy received a rating of 9.8 out of a possible 10. A Study at the University of Florida in Jacksonville found that patients who attended Tai Chi classes for one hour each week for 12-weeks were less likely than a group of control patients to experience an increase in the severity of their condition and a decrease in motor function. . . .[of alternative therapies] the most popular therapies being Tai Chi, yoga, and acupuncture. , The Atlanta Journal Constitution reported, “Parkinson’s Meets It’s Match in Tai Chi.” In this article they write that Dr. Mark Guttman, director of the Centre for Movement Disorders in Markham, Ontario, recommends people with Parkinson’s do exercises that involve a lot of stretching, similar to the movements of tai chi.
“Tai chi is wonderful; it can help people with disabilities as well as people with Parkinson’s,” he says. He added that studies on animals show exercise induces a change in the brain that prevents the symptom’s of Parkinson’s from emerging.
The Tai Chi teacher for this program, Ms. Embree, spoke of how people with fibromyalgia, multiple sclerosis, cystic fibrosis, and Parkinson’s often attend her classes . . . “Doctors are now sending people here,” adds Ms Embree. (for the entire article, go to: PARKINSON’S MEETING IT’S MATCH IN TAI CHI, April, 13, 2005, At the National Parkinson’s Foundation site, Melanie M. Brandabur, MD NPF Center of Excellence, University of Illinois at Chicago and Jill Marjama-Lyons, MD NPF Center of Excellence, Shands Jacksonville, wrote, “Most patients derive a great deal of benefit from today’s medications and surgical therapies for Parkinson’s Disease . . . However, benefits of these therapies can be limited. As time goes by, the medications may not seem as effective as they once were. Side effects or unpredictable response may develop. Surgical therapies are not curative and often treat only selected aspects of Parkinson’s Disease.
Brought to you by:http://www.freeeboooks.com
Recommended Free Ebooks:
http://www.freeeboooks.com/health-and-fitness/Complete-Body-Fitness.html
http://www.freeeboooks.com/health-and-fitness/Dr-Atkins-New-Diet-Revolution.html
About the Author
Find thousands of free ebooks for your iPad, Kindle or any ebook reader and more… If you are a digital seller, all our ebooks have full re-sale rights.
see www.cellmedicine.com
Video Rating: 4 / 5
The treatment commences with stem cell extraction by Liposuction.
Multiple sclerosis is an inflammatory neurological disease that can generate a wide range of physical and psychological symptoms. Multiple sclerosis involves the deterioration of myelin, a substance that surrounds the body’s nervous cells. Myelin has a very important role in the transmission of nervous impulses, and if this substance is affected, the entire activity of the nervous system is seriously compromised. Although the actual causes of multiple sclerosis remain unknown, there are several hypotheses that present genetic abnormalities as the main factors responsible for causing the disease. Medical scientists believe that multiple sclerosis occurs on the background of inherited genetic predispositions, and environmental factors are suspected to be triggers of the disease. Some hypotheses also introduce viral infections in this scenario, although infections with viruses don’t seem to contribute to the development of the disease.
Multiple sclerosis can affect the body on different levels. The majority of people with multiple sclerosis suffer from dysfunctions of the muscular system, while others also develop neuropsychological dysfunctions. Multiple sclerosis usually generates a wide range of symptoms: body weakness, pronounced fatigue, muscle numbness, poorly coordinated moves, poor balance. People affected by multiple sclerosis can in time experience decreased visual acuity, mental states of confusion and even short-term memory loss. People with multiple sclerosis can also suffer from depression, which is common in more than 80 percent of patients with the disease.
Although there is no cure for multiple sclerosis, most medical treatments can alleviate the symptoms generated by the disease, also preventing their recurrence. However, the majority of medications prescribed in long-term multiple sclerosis treatments (beta interferon, corticosteroids) can generate many side-effects, causing additional damage to the body. Hence, it is best to avoid following long-term treatments with potentially-harmful drugs. In many cases, multiple sclerosis therapies can ameliorate physical symptoms just as well, without using any drugs. Considering the fact that most symptoms generated by the disease are linked to the musculoskeletal system, the majority of multiple sclerosis therapies are focused on improving muscular mobility and tonus through physical exercise. Multiple sclerosis therapy through exercise can help patients regain their strength, coordination and balance, alleviating muscular pain, numbness and stiffness.
The majority of multiple sclerosis therapies involve recuperative physical exercises and medical gymnastics. Other forms of multiple sclerosis therapies include recreational physical activities, such as swimming, jogging or the practice of different sports. Most people who have followed such multiple sclerosis therapies have experienced an amelioration of their physical symptoms and have improved their overall health condition. Although medical treatments are required for most patients, people who follow multiple sclerosis therapy need smaller doses of medications. Combined with an appropriate diet and a healthy lifestyle, multiple sclerosis therapy through exercise can be very benefic.
We recommend you clicking this site http://www.multiple-sclerosis-center.com for more multiple sclerosis subjects like multiple sclerosis information or multiple sclerosis diagnosis
We recommend you clicking this site http://www.multiple-sclerosis-center.com for more multiple sclerosis subjects like multiple sclerosis information or multiple sclerosis diagnosis
Article from articlesbase.com
Find More Multiple Sclerosis Diagnosis Articles
XYZ-Wellbeing ReTreat Facility are the only people who have experience in this IV Therapy. It is wrong and can be dangerous to do this therapy with-out a skilled person assisting you. These above specialists have the benefits of my many 40 years experience in the field of Cancer and specializing with what I believe is the best, High PH therapy.
DrPablo at a new clinic opening early in 2009 www.XYZ-Wellbeing.com Dr Pablo heads up the team in a new six year Cancer Trial On Alternative Treatments in Combination. They run for the FIRST 21 DAYS of each month commencing with a weekend workshop the first Saturday of each month. This is a holistic combination that will give you the best possible outcome using these therapies.
Stage 1 has a detoxing and strengthening preparation program for 21 days, & Ozone. Stage 2 Followed by Dr Sartori Ozone and High PH Program month 2 over 21 days. Stage 3 A Recharge and rebuild program that included very high Vitamin C, Hyperbaric Oxygen, Colonic Irrigation, Immune stimulants, just to name a few of the services.
With a relaxing pampering week in between with organic food, massage and many qualified Alternative Practitioners and supportive staff, this clinic is unique.
The programs at XYZ-Wellbeing.com include Ozone, Vitamin B17, also referred to as laetrile, Enzyme Therapy, Vit C for Cancer & Detoxing and or wellness enhancement programs every day, as well as mind therapy and meditation.
Please read all of the Dr Sartori Papers
and only use this program with a supportive practitioner as like all therapies,
side effects can be dangerous,
for example: you can even drown with to much water.
These minerals, Ozone and the holistic approach, when combined carefully
using Dr Sartori s formula, is safe.
However in the wrong combination or hands can be dangerous.
Part 1 HOW TO TURN CANCER INTO A NEW LEASE ON LIFE
I am proud to announce that the Enhanced High-pH Therapy of Cancer
originally conceived by the world-famous bio and nuclear physicist
A. Keith Brewer, Ph. D. and
enhanced by the undersigned
is once again available through www.XYZ-Wellbeing.com ReTreat Facility
This cancer therapy is based on Natures way of getting rid of cancer. It simulates the life condition of the longevity populations of this world, all of which seem to have many factors in common. These people, many of which live well over 120 years in excellent health, are almost exclusively found in high altitudes of 2000 m (7000 ft) and above. They breathe clean air enriched with tiny amounts of ozone. They drink pure mountain water that flows right of the glaciers. They grow their own food that is rich in vitamins and minerals. Their stress level is low and they are in harmony with their environment.
Their spiritual beliefs demand from them to respect all other living beings. It is interesting to note that of the three people with the greatest longevity, two – the Hunzas in Northern Pakistan, and the Abkhazians in the Caucasian Mountains of Georgia near the Black Sea – are devout Muslims, the third, in Vilcabamba, Ecuador, mostly follow Native American Indian animistic beliefs.The first unusual ingredient of the environment of the longevity population – ozone is highly activated oxygen consisting of three atoms. This triatomic oxygen is the most powerful purifier of the Earth and of all living beings. In the simplest terms, ozone is capable of burning all poisonous substances at temperatures between 10 to 40 degrees Celsius (50 to 104 degrees Fahrenheit), as well as killing all bacteria, viruses, and other microorganisms that may contribute to cancers.
Ozone is produced by the action of ultraviolet sun light on the oxygen in the air. The higher up we go, the more ultraviolet, and thus, the more ozone. Since time immemorial, it was known that women, who grew up in lowlands, would not get pregnant for at least six months if they moved to altitudes of 3600 m (12000 ft.) or higher. We believe now that ozone naturally prevents a pregnancy until these women are fully acclimatized to high altitudes. In the same way, as ozone temporarily stops the growth of the embryo, it also stops the growth of any fast growing cancer.
We know from the research of Prof. Dr. Otto von Warburg in the 1920s that the cancer cell acts like a plant cell and is dependent for its energy metabolism on lactic fermentation. Fermentation is 19 times less effective than oxidation, the normal energy metabolism of the entire animal kingdom. Fermentation is very sensitive to minute amounts of ozone and there are virtually no cancers observed in people living in altitudes above 2100 m (7000 ft.).
All longevity populations live on a diet rich in certain vitamins and minerals that have been proven effective in preventing cancer. Most important among these nutrients are vitamin C (ascorbic acid and ascorbates), vitamin A (retinoic acid and derivatives) and beta-carotene, vitamin E (mixed tocopherols), vitamin D2 from UV irradiation of ergosterol, the high-pH minerals cesium (Cs), rubidium (Rb), and potassium (K), and the trace minerals zinc (Zn), selenium (Se), molybdenum (Mo), and vanadium (V). These nutrients are found in the home-grown vegetables and fruits that are mostly eaten within a few hours after they are harvested. Needless to say, they are grown organically, without the use of harsh chemical fertilizers and pesticides. Most of the drinking water is glacier run-off, called milk of the mountains that is rich in rubidium and cesium. Magnesium (Mg), with calcium (Ca), essential for the transport of oxygen into cells, and potassium (K) with Mg, the most important intracellular electrolytes, are abundant both in green vegetables and drinking water consumed by longevity populations. It is interesting to note that most longevity populations go through prolonged periods of fasts on a yearly basis, be it during the month of Ramadan or during the leaner part of the year before the crops are harvested.
If ozone in higher doses is applied intravenously, it is effective not only to prevent cancer, but to reverse many cancers, especially cancers of the lungs, liver, pancreas, and metastatic cancers to the bone, as is well documented in the medical literature. Doctor A.K. Brewerâs high-pH therapy, using high doses of cesium (or rubidium), and enhanced by weak acids such as ascorbic acid (vitamin C) and retinoic acid (derived from vitamin A) , as well as ampholytic elements such as zinc and selenium, has been proven effective in virtually all fast growing cancers, both after oral and intravenous application. This is further enhanced by amilonitriles contained in apricot pits that are part of the regular diet of the Hunzas, and may also be applied intravenously in the form of Laetrile.
The intravenous form of the enhanced high-pH therapy also contains generous amounts of the intracellular electrolytes magnesium and potassium. The dosage of the I.V. therapy is adjusted to reduce virtually all smaller cancer accumulations (up to 20 or 30 cm diameter), providing that they are fast growing tumors, by one to two centimeters per day (2/5 to 4/5 per day). Large tumor masses are reduced with the I.V. therapy by 500 to 900 grams per day (1 to 2 lbs. /day) to prevent an over-loading of the bodies metabolism and excretion with tumor breakdown products. The critical factor is the kidney and liver function of the cancer patient before the enhanced high-pH therapy is started. One important thing to keep in kind is that, though the enhanced high-pH therapy was seemingly effective, some patients may still succumb from the adverse effects of cancer chemotherapy, or from complications of radiation or surgery undergone previously. Also, if a cancer patient, after the tumor disappeared with the high pH therapy, does not change his lifestyle and eating habits, cancers may develop again in his or her body.
How does all of this work?
Most orthodox cancer chemotherapy proffers only a large number of unproven theories and in almost all cases shortens the survival after severe suffering form its adverse effects1. On the other hand, the enhanced high-pH cancer therapy is proven effective by clinical and experimental studies that filled over two thirds of Supplement 1, to the major peer-reviewed medical journal Pharmacology, Biochemistry, and Behavior, of December 1984 [21 Suppl 1: 1-135]2.
Also, on this therapy, almost all patients, no matter how far gone or suffering from the adverse effects of chemotherapy and/or radiation, will feel much better within a few days. Particularly, cancer pain, even if unresponsive to the most powerful pain killers, in most cases disappears within only a few hours after starting the cesium.
Any symptoms connected with this therapy, particularly from the I.V. ozone, are almost always the result of a healing crisis, well known to homeopaths for over 200 years. These symptoms may be quite uncomfortable but subside in most cases within a few hours, and many patients report that afterwards they felt better then ever before in their lives.
1 See Appendix II to the author’s two Cancer Articles: “Nutrients & Cancer” and “Cesium Therapy in Cancer Patients”, Pharmacol Biochem Behav 1984; Suppl 1: 7-10 & 11-3, respectively.
2 See Appendix I to and also the author’s two Cancer Articles of 1984.
In the following we will briefly explain how cancers form (i.e., carcinogenesis) and how the enhanced high-pH cancer therapy transforms cancer cells either to normal cells or makes them disappear altogether.
Professor Dr. Otto von Warburg, double Nobel laureate, in medicine and biochemistry, in the 1920s discovered the fundamental mechanism of carcinogenesis. When certain cancer-causing chemicals (carcinogens) attach to the cell membrane, the oxygen carriers calcium and magnesium are unable to enter these cells. The resulting oxygen starvation causes these cells to regress to anaerobic (i.e., without oxygen) metabolism [which is 19 times less effective than aerobic (with oxygen) metabolism, as was stated previously].
The end product of anaerobic breakdown of glucose is lactic acid which renders the cell acidic. This acidosis, in turn, causes the genetic changes that result in the uncontrolled growth of cancer cells. The pH in cancer cells, because of the lactic acid buildup, lowers from about 7.2 to 7.0 (in fast growing tissues) to between 6.8 and 6.0, and in some fast growing metastases to even 5.5. This renders cancer cells extremely vulnerable to ozone and alkalinity which, if applied in minute amounts, either normalizes or destroys them.
Specifically, intravenous ozone has the four major effects in cancer patients.
One, it removes homeopathically whatever disposed a specific organism to cancer and this causes the healing crisis. This healing crisis may be quite uncomfortable subjectively (though lasting at most a few hours), but there is less than a one in a million chance of serious complications.
Two, ozone removes all toxic and carcinogenic chemicals, amoebas, viruses, bacteria, and other agents from the body that may in some way contribute to cancer and this may be the reason why it seems to be cancer preventative.
Three, ozone inhibits any fast and uncontrolled growth typical for cancer cells.
And four, ozone has a well documented immuno-stimulating effect that helps both with the protection from cancer and with the removal of cancer cells destroyed by the high-pH therapy, enhances the body’s resistance to infections, and boosts longevity.
The more acidic the cancer cells, i.e., the lower their pH, the more vulnerable they are to alkaline, or high-pH, agents. While normal cells are not permeable for cesium or rubidium, and require a transport mechanism for potassium, these three alkalizing elements freely diffuse into cancer cells. This causes the pH to raise in cancer cell; and the higher the pH in the cancer cells, the faster the cancer breaks down. If the intracellular pH is raised to above 8.5, you can actually see the skin wrinkle while you watch over areas where there previously was a superficial cancer tumor, e.g., a breast cancer.
This diffusion of alkalizing elements is enhanced by ascorbic acid (vitamin C) and retinoic acid (from vitamin A). Zinc and selenium further enhance the penetration of cesium, etc., by broadening the electron donor capacity of the cell membrane. Zinc and selenium are also powerful immunostimulants, and help with the removal of tumor cells by phagocytotic (lit. cell-eating) neutrophil leukocytes (white blood cells) and monocytes (also called macrophages or â big cell-eaters). Selenium, vitamin E, and beta-carotene are powerful antioxidantts that scavenge dangerous free radicals. Vitamin E also prevents the toxicity of high doses of vitamin A. Molybdenum enhances cancer-destroying oxidases, and vanadium assists with lipid and fatty aid metabolism for faster breakdown of cancers.
What is the reality of the 2004 State of the Cancer Treatment in the U.S.A.?
After 35 years of war-on-cancer, and almost $ 90 billion of research funding by the U.S. Government, the cancer death rate in the U.S. of A. increased almost six-fold from 145,000 in 1970, to an estimated 850,000 for 2004. Each insured cancer patient is presently worth between $ 150,000 to $ 500,000 (average about $ 200,000) to the medical profession, hospitals, and the pharmaceutical industry. The out of pocket expenses for insured patients range from $ 30,000 to 100,000, average about $ 40,000, whereas the ULS Cancer Therapy is offered at $ 16,000.00 / €14,000.00. The total national expenditure for cancer management to the premature death of over 800,000 people per year exceeds $ 100,000,000 ($ 100 billion), and, in addition, there are economic losses of the families of the prematurely deceased of perhaps $ 120 billion if their lives had been saved by effective alternative therapies.
This total financial investment for patients undergoing the enhanced high-pH cancer therapy is about one-half to one-tenth of the out of pocket expenses of the average insured cancer victim undergoing conventional orthodox cancer therapies. Best of all, the success rate with the enhanced high-pH therapy is consistently much higher and in many cases over 95%, particularly if you are not suffering from severe toxicity of chemotherapy or from radiation damages. And this includes proven incurable (i.e., by orthodox therapies) cancers of the lungs, liver, pancreas, brain, prostate, breast, bones, melanomas, lymphomas, sarcomas, and leukemias.
Because of the potential (especially, financial) impact of the enhanced high-pH therapy on the medical/hospital/pharmaceutical industry complex and their most powerful lobby in Washington, D.C., and in many State Governments, this effective, economical, non-toxic treatment can only be offered offshore, i.e., at a location outside the United States. However, every effort is made to have these offshore hospitals properly accredited and to have the costs of the treatments reimbursed by most insurance carriers. The first of these locations is now available in Northern Thailand at a first class hospital for Alternative Medicines that, Insha’Allah, will be upgraded to the point that it is eligible for Blue Cross insurance payments. (Added update) and also at XYZ Wellbeing ReTreat Facility and Research Cancer Centre in Located in the the beautiful Cartagena South America. Visit www.xyz-wellbeing.com and go to the why choose us link for more cesium information and cancer research.
Therefore, if you, or any of your loved-ones or friends have cancer, even if it was so far ân incurable with chemo, radiation, and/or surgery, please contact The above to see if you may be eligible for the enhanced high-pH therapy. We are committed to one thing only ând to return you to your mental, emotional, and spiritual wellbeing. As long as you faithfully follow the path that we map out for you, you have an excellent chance of emulating the joyous, vigorous longevity of the people who served as the models for the enhanced high-pH therapy. However, it cannot be stressed enough, that the shrinking of a tumor is by far the lesser part of overcoming cancer.
Much more important for lasting success is to overcome the cancer personality, defined in the 1960s by Lawrence LeShan, and to embark on an overall healthy lifestyle that equals and excels (by more advanced knowledge) the one the longevity populations. And, perhaps, most important is your will to live and your absolute need to have to accomplish things that must not be left undone by your premature death from cancer. By taking charge of your life in this manner and by taking responsibility by following our leads in all aspects of your life, you will make it possible not only to become free of cancer but remain free of it permanently.
We can only lead you to the Path.
It is up to you to walk it and to make sure that everyone around you walks it with you and all the way!
No matter what, always keep in kind that, fundamentally, the Lord wills the ultimate outcome of everything in your life. Just as the Lord lead you to the enhanced high-pH therapy to get rid of your cancer tumor, and to the comprehensive Ultralifescience Program for physical, mental, emotional, and spiritual wellbeing, the extent to which you will succeed with it is entirely as the Lord wills. Our promise to you is simply that we will leave no stone unturned to provide for you all the tools for your success in this endeavor.
To your abiding health, vigor, and happiness!
__________________________________
Abdul-Haqq H.E. Sartori, M.D.
NOW THAT YOU HAVE LEARNED THAT YOU HAVE TERMINAL / INCURABLE CANCER
Cancer is perhaps the most feared disease on Earth since more and more people find out that the treatments offered for it in modern hospitals – surgery, radiation, and chemotherapy – seem to help only a small percentage of people who, in most cases, suffer from crippling mutilations and burns (from surgery and radiation), or severe, often life threatening, side effects from the poisonous chemicals used for chemotherapy.
Don’t despair! There is still hope for you!
Even if your doctor sends you home to die perhaps telling you “We have done everything we know, there is nothing else we have to offer to help you, except letting you die in peace”.
Did you ever wonder that before about 1900, cancer was a rare disease and that in some parts of the world there is NO CANCER at all? Research that goes back to Dr Otto von Warburg in the 1920s revealed the true nature of cancer and Dr A. Keith Brewer since the 1950, in part through investigation of cancer-free populations, formulated an effective treatment for cancer. This treatment was applied to many cancer patients and further enhanced by Dr Sartori since1980.
Almost all cancers in over 700 patients treated so far with this enhanced high pH therapy, responded within a few days and with I.V. application, daily shrinking of tumors between 1.0 and 2.0 cm can be expected. The only discomfort from this treatment comes from a “healing crisis” reaction that leaves you, after some initial discomfort, feeling better after a few hours or, at most, a day or two. How does this all work? Dr von Warburg found that cancer cells, like plant cells, function without oxygen and thus are very sensitive to oxygen and very strong alkaline elements. Because of the lack of oxygen, cancer cells break down their fuel, glucose, to lactic acid. This causes cancer cells to become acidic (i.e., the pH in the cancer cell is lowered to 6.8, even 5.8) which, in turn, causes them to grow out of control. Alkaline elements, particularly cesium, but also rubidium and potassium can freely enter cancer cells (but not normal cells) causing them to become alkaline or raise the pH in the cancer cell. This raised pH slows down the cancer growth and at a pH of 8.0 all cancer cell growth stops and the cancer cells either die or are turned into normal cells. While we all depend on oxygen to survive, cancer cells die if exposed to oxygen and, particularly, its most powerful form, ozone. People who live very long are free of cancer, is a fact that prompted Dr Brewer to investigate their nutrition and found that their diet contains the alkaline elements cesium (Cs), rubidium (Rb), and potassium (K), and other nutrients that were found to reduce the cancer incidence such as zinc (Zn), selenium (Se), molybdenum (Mo), vanadium (V), and the vitamins A, C and E, as well as amygdalins from apricot pits. After extensive studies of cancer cell cultures, Dr Brewer found the following: Zinc and selenium attach to the cancer cell membrane and make it easier for the cesium and rubidium to enter the cancer cells. Vitamins A and C are weak acids that attract these elements to the inside of cancer cells. Magnesium (Mg) and calcium (Ca) that normally transport the oxygen into cells are depleted in cancer cells. These and other findings were the basis for Dr Brewer to formulate the high pH therapy for cancer. His method was enhanced in the 1980s by adding I.V. ozone (which is the most active form of oxygen), herbal combinations, and other modalities, which made it even more effective.
Up to 98% of animals with cancers were cured by Dr Brewer’s high pH therapy.
Tests on mice fed cesium and rubidium showed marked shrinkage in the tumor masses of abdominal implants of mammary tumors (“breast cancers”) within 2 weeks. In addition, the mice showed none of the side effects of cancer. Cesium chloride, zinc gluconate and vitamin A were used together to alter growth of colon cancer implants in mice and the use of these compounds was responsible for the disappearance of tumors in 98% of the animals. Sarcoma I implants in mice and Novikoff hepatoma in rats disappeared if the proper ratio between cesium and potassium was maintained. With Dr Brewer’s complete protocol, using cesium (&/or rubidium), potassium & magnesium, vitamins A, C, & E, zinc, selenium, & amygdaline, there was a prompt reduction of all tumors treated by Dr Sartori including lymphomas in cats and dogs, skin cancers in dogs, cancers of the mammary glands, mouth , and esophagus in horses, and cancers of unknown primary in chickens.
Like with all “nutritional” treatments, the principle of the weakest link of the chain holds true, and if even one essential nutrient is lacking, the treatment may fail. In virtually all of over 700 patients with different types of cancer, the enhanced high pH therapy was effective in reducing the tumor mass. Over 90% of these patients were terminal with extensive metastasis and had received maximum conventional cancer treatments. Malignancies treated with this protocol included cancers of the lungs, liver (& gallbladder), pancreas, breast, prostate, colon & rectum, stomach, brain, cervix & uterus, ovaries, testicles, adrenals, kidneys & bladder, of unknown primary, rectovaginal, etc., as well as lymphomas & leukemias, melanomas, & sarcomas & bone. The results with the LSU/ULS Cancer treatment in 100 cancers are detailed in the attached articles. Summary of and Comments on the LSU (now ULS) Cancer Treatment Results. There are several factors that should be pointed out with regard to the data summarized in Table I
(a) Out of over 500 cancer patients treated from 1980 to 1987, only 97 fulfilled the criteria of having been followed up for at least 5 years or until their death. This might negatively bias the number of patients that have died by a factor of up to five since almost all of the over 500 patients were followed for at least 3 months.
(b) According to Arlin J. Brown (AJB), cancer survival statistics as published by the National Cancer Institute (NCI) are not point-to-point, but are determined from the number that can be located 5 years after being diagnosed with cancer (and not even the beginning their first treatment, e.g., at) at NIH/NCI. In cancers with high mortality such as small cell lung cancers (1.0% 5-year survival according to NCI) and pancreas cancers (3.0% 5-year survival according to NCI), AJB found point-to-point survival rates of less than 0.01% and less than 0.05% respectively (perhaps because >99% of the patients had died so long ago that they could not be located anymore).
(c) By far, the majority of the patients seem at LSU were using our therapy as their last resort after all other treatments (both conventional & alternative) had been unsuccessful and most patients were simply sent home to die.
(d) In view of the extremely unfavorable patient population as outlined under (a) through (c), we believe that the results of the LSU treatment are quite remarkable and by far the best offered anywhere in the world.
(e) For reasons beyond the control of the authors, only about 200 cancer patients were treated from 1988 through 2003. In all of these patients, ozone and the minerals and vitamins were applied intravenously (I.V.). The I.V. application of minerals and vitamins proved to be a dramatic improvement in that (i) in virtually all cases, the size/diameter of all fastgrowing tumors was reduced by 1.0 to 2.0 cm (0.4 to 0.8 inches) per day, i.e., a disappearance of a 5.0 cm (2 inch) tumor within four days and of a 10 cm (4 inch) tumor within eight days, and (ii) virtually none of the patients showed any of the side effects frequently encountered with oral vitamin/mineral application such as nausea, diarrhea, abdominal discomfort, possible aggravation of ulcer symptoms, and sometimes even vomiting.
After several cancer patients were successfully treated at the Integrated Medical Center in Northern Virginia from April to July 1998, from mid 1998 until mid2003, government agencies and law enforcement in the U.S.A. virtually completely suppressed the use of the enhanced high–pH cancer therapy by LSU/ULS, and this treatment can now only be offered offshore and far removed from these agencies.
RESULTS WITH THE LSU/ULS TREATMENT PROGRAM FOR CANCER
(broken down into the most frequent types/locations of cancers treated) 1. Lung Cancers Of the 18 lung cancers described in this study (of a total of >100), 14 were connected to active smoking, two to passive smoking, one to radon exposure in the home, and one to cadmium exposure at the workplace. Asbestos may have been a factor in one of the active smokers, radon in the home in one of the passive smokers.
Beta-carotene, vitamin A, selenium, and vitamin E from green and yellow vegetables are now recognized as clearly preventative of lung cancer. These vegetables were conspicuously absent from the diet of most of our lung cancer patients. Instead, most of them were eating a meat and potato diet before they started the LSU cancer treatment program. Histologically, 4 patients had epidermoid cancers, 3 had adenocarcinomas, 8 had small cell carcinomas, 2 had large cell carcinomas, and in 2 patients the histologic type was unknown; two of the small cell carcinoma patients also had a lymphoma. All patients had received the full course of orthodox treatment: 6 had surgical resections (3 of the epidermoid-, and one each of the adeno-, small cell-, and large cell carcinomas). All patients had received chemotherapy, and the 6 surgical patients also had received radiation. At the beginning of the treatment, four of the patients were dying on a stretcher, four could walk only with assistance, six were given a prognosis of less than 6 months of survival, and in 4, the prognosis was unknown. The 2 patients with unknown histology who came in dying on a stretcher nevertheless survived 13 and 20 days respectively. The third of the dying patients, with an epidermoid cancer, survived almost 3 months until he died from internal bleeding from an extremely low platelet count. The fourth of the dying patients survived over 5 years and was well in July 1992; he had a small cell carcinoma that generally has less than 1% chance of 5 year survival (less than 0.01% according to Arlin J. Brown). One of the two small cell carcinoma patients who also had a lymphoma is alive and well without any sign of cancer over 10 years after he was barely able to walk into the office with assistance. He is now in excellent health and successfully runs a medical equipment company. The other unfortunately died in a hit-and-run car accident 10 months beyond his given life expectancy and without any sign of cancer at autopsy. One of the adenocarcinoma patients who came in, walking with assistance, responded well for about 2 weeks, then continuously deteriorated, and died after 4 months. The fourth walk-assist patient, with a large cell cancer was treated 4 times and died after 1 year and 8 months. Of the 6 patients who were given fewer than 6 months to live, one epidermoid cancer patient died from cardiac failure after 3 years and 4 months, one of the small cell cancer patients with terminal emphysema died from a combination of pulmonary failure and bronchopneumonia; one patient with adenocarcinoma received 6 treatment series and died from his cancer after 3 years and 8 months; one small cell cancer patient died after 2 years 5 months, one after 4 years 1 month, one epidermoid cancer patient died after 3 years 3 months. One of the factors in the deaths of these patients may have been that at the time of their treatments, the LSU mental reconditioning program (MRP) was far less developed. By using the full, presently available LSU MRP, perhaps at least two, maybe even four of these patients could have been helped. Of the lung cancer patients who survived over five years, four had a small cell cancer, one had a large cell, and one had an epidermoid cancer. 2. Lymphomas Of the 13 lymphomas described in this study (of a total of >60), 9 were lymphocytic (3 males had AIDS, one male had severe rheumatoid arthritis, and one was a Klinefelter syndrome; 4 were females), one female had Hodgkin lymphoma, one male had a T-cell lymphoma, and in 2 males, the histology was not determined. Three patients were dying, 4 needed ambulatory assistance partially because of their enormous tumors, and 3 were given less than a year to live. One of the dying patients with lymphoma of unknown histology died after 17 days from cardiac toxicity of chemotherapy. Another of them, an AIDS patient, died after 7 weeks from aplastic anemia from combined chemotherapies for infections and the lymphoma, given to the patient prior to his coming to LSU. No signs of lymphoma were detected at time of death. One 37 year old dying woman has survived over 10 years without any sign of recurrence after only one series of the LSU treatment.
Of the 4 patients who needed assistance with walking, one AIDS patient is alive and well for over 8 years, has turned HIV negative at the end of one treatment series and his T4 cell count rose from 124 with a T4/T8 ratio of 0.36 to between 1,100 and 1,300 with a T4/T8 ratio between 1.5 and 1.8 for the last 4 years. Within one month, his nodal lymphomas disappeared and none of his previous CNS involvement was detected anymore on a CAT scan. One patient had a huge hemispheric protrusion of his abdomen, very similar to a patient described in Pharmacol. Biochem. Behav., Vol. 21, Suppl. 1, pp. 11-13, 1984. His total tumor mass was estimated to be about 37 kg with about 40 liters of ascites. Within 3 weeks both tumor and ascites were reduced to approximately one half, within 2 months there was only a slight enlargement of the spleen of about 5 cm. The patient survived for over five years without any sign of tumor recurrence. The two patients who had both lymphoma and lung cancer were already discussed under 1.; one of them is alive and well, the other died 10 months after treatment in a hitand- run accident. He had shown no signs of cancer at autopsy. One of the 3 patients who were given less than a year to live, unexpectedly died from a heart attack 10 months after initial treatment. Another died after 3 years and 7 months and did not respond to treatments, except for the initial series. The third patient survived for over 5 years without sign of tumor recurrence. The woman with Hodgkin lymphoma died from aplastic anemia, a complication of her previously received chemotherapy, 1 year and 2 months after treatment onset. The patient with the T-cell lymphoma had come all the way from Osaka, Japan and seemed to respond well to the first treatment series. He returned 5 months later, showed barely any response to the treatment, and died 11 months after the initial visit. Language problems may have been a contributing factor to his death, since we were not sure, whether he and his family had completely understood our instructions. 3. Liver Cancers Primary hepatocellular carcinoma (HCC) or malignant hepatoma is one of the most common malignancies in the world and it is estimated to be responsible for up to 1,300,000 deaths every year. In portions of Africa and Asia, HCC is the most common malignant tumor. It occurs infrequently in the U.S., North and South America, and Europe where it accounts for about 2% of the malignancies. The incidence of HCC is especially high in China, Taiwan, Mozambique, and Singapore. Risk factors of HCC include chronic toxic hepatic injury (20 to 60% in N&S America), cirrhosis (60 to 90% worldwide), chronic hepatitis B infection (20 to 90% worldwide), aflatoxin (especially in Africa and Asia, e.g. from peanut oil), alcoholism, chronic hepatic outflow obstruction (CHOO; 20% in South Africa, 60+% in Japan), male gender (5:1 in high incidence areas, 2:1 in low incidence areas), Asian or Black ancestry (or rather dietary habits). Of the 12 patients listed as having liver cancer (of a total of >50), 8 had primary HCC, 3 had extensive liver metastasis from an occult primary malignancy (OPM), and one patient had intrahepatic biliary cancer (IHBC).The 8 patients with HCC had elevated alpha fetoprotein (AFP) and reduction of AFP below 100 mg/mL was interpreted as an indication of tumor disappearance. Using a cutoff for serum levels of 10 ng/mL, AFP is sensitive for HCC in 70 to 90%. Patients with cirrhosis and chronic hepatitis tend to have elevated AFP levels of usually under 200 ng/mL. Levels of 400 to 1,000 ng/mL are diagnostic for HCC. AFP is also elevated in yolk sac tumors and in a high proportion of other germ cell tumors.
The patient with IHBC and the 3 patients with liver metastasis from OPM had elevated carcinoembryonic antigen (CEA) in the range of 55 to 185 ng/mL at their admission to the LSU cancer treatment program. No colorectal cancer or other primary malignancy was ever found. Elevated CEA levels are found in patients with gastrointestinal, pancreatic, breast, lung, thyroid medullary, and genitourinary carcinomas, as well as in benign disorders including inflammatory bowel disease, cirrhosis of the liver, pancreatitis, and pneumonia. Normal values for CEA are up to 2.5 ng/mL, in smokers up to 5.0 ng/mL. Benign disorders seldom elevate the CEA level above 10 ng/mL. Reduction of CEA levels below 5 ng/mL was interpreted as an indication of tumor disappearance. Of the 12 liver cancer patients, 3 were dying, 3 needed assistance when walking, and 4 were given life expectancies of less than 6 months. 9 had undergone surgery, including the 3 OPM and the IHBC patients; 5 had suffered radiation treatment, and all 12 had been exposed no massive chemotherapy. One female HCC patient, a 32-year-old fitness instructor, had been first seen in the office of a world famous diet doctor in New York City, where she almost died on the table from an imbalanced vitamin-mineral IV. Through almost a miracle she made it to Washington, D.C., lying on a stretcher in the station wagon driven by her husband. Within 2 weeks her massively enlarged liver that had extended over 14 cm below the normal in a scalloped curve that filled about two-thirds of her abdomen, had returned to normal. Her AFP test came down from 2,420 ng/L to 120 ng/mL within 24 weeks. She was well until about 4 years later when she died in a car crash. Unfortunately, the diet doctor never referred any other cancer patient to the LSU clinics. Four more of the HCC patients, and one of the OPM patients, responded very well and survived over 8 years after their initial treatment without signs of recurrence, with AFP and CEA below the cutoff points of 100 ng/mL and 5.0 ng/mL respectively. One HCC patient died from the side effects of chemotherapy within 2 weeks, another within 2 months; one OPM patient shared the same fate after fewer than 3 months. The IHCP survived 2 years and 4 months, after responding moderately well to 3 courses of the LSU cancer treatment. 4. Pancreas Cancer The tumor-associated carbohydrate antigen, CA 19-9, detects about 80% of all pancreatic cancers correctly, compared with 8% of patients with pancreatitis and 1% false positive normal patients. The pancreatic adenocarcinoma glycoprotein, DU-PAN-2,. detects up to 55% of all pancreatic cancers, though in may also be elevated in patients with biliary cirrhosis, gastric cancer, and biliary cancer. In all of our 11 pancreatic cancer patients(of a total of >50), either CA 19-9, DU-PAN-2, or both markers were elevated to a range of 850 to 950 U/mL for CA 19-9, and 300 to 1,200 U/mL for DU-PAN-2 at admission, and reductions of serum levels below 70 or 120 U/mL, respectively, were considered as evidence of disappearance of the tumor. CA 19-9 antigen (detectable by a murine IgG1 monoclonal antibody against a human colon carcinoma cell line) is elevated in 55 to 90% of stomach cancers, 80% of pancreatic cancers, and about 95% of colorectal cancers; in advanced pancreatic cancers it is elevated in 80-90%. In benign disorders including acute pancreatic, hepatobiliary disease, and inflammatory bowel disease, CA 19-9 usually does not exceed 100 U/mL. Normal values of CA 19-9 are up to 36 U/mL. DU-PAN-2 is a mucin-type glycoprotein antigen selected for reactivity against human pancreatic carcinoma cells (detectable by murine monoclomal antibodies). Increased levels occur in many diseases of the liver and hepatobiliary tree including primary biliary cirrhosis, sclerosing cholangitis, hepatitis, cirrhosis, and benign hepatomas, and usually do not exceed 200 U/mL. DU-PAN-2 may also be elevated in biliary and gastric cancer, and in primary hepatocellular carcinoma (HCC). Normal DU-PAN-2 values are up to 60 U/mL. Histologically 10 of the 11 patients had an adenocarcinoma of the pancreas, one had an intrapancreatic bile duct carcinoma (IPDC) that was diagnosed intraoperatively. One patient had both stomach and pancreatic cancer. Eight of the patients had undergone resections and/or exploratory surgery, 10 had suffered from radiation, and all 11 had been given massive doses of chemotherapy.
At the onset of the LSU treatment,
one patient was dying, 3 needed walking assistance, and 6 were given fewer than 6 months to live.
Two patients died from the side effects of chemotherapy within less than 3 weeks including the patient with IPDC. One other succumbed from chemotherapy side effects after 10 weeks. One patient died after about 10 months from an internal bleeding probably not related to cancer. The patient with stomach and pancreatic cancer did not respond well to 3 treatment courses. Nevertheless, they prolonged his life from an expected less than one month to 1 year and 7 months. One patient died after 3 years and 2 months, another after 3 years and 11 months. Nevertheless, the treatment had extended their life expectancy of less than 6 months. Four of the 11 patients survived more than 5 years which compares favorably with a reported 5-year survival rate of pancreas cancer patients of 3% (or less than 0.01% according to Arlin J. Brown). 5. Breast Cancer Six of the nine breast cancer patients (of a total of >40), who are discussed in this report were terminal with widespread metastatic disease, one of them dying, two of them needing walking assistance, and another three with a life expectancy of less than 6 months. In all cases, any detectable primary tumors or metastatic skin tumors either disappeared within 2 weeks or turned from hard, knobby, scalloped, infiltrative cancerous growths into much smaller well-defined, round, and much softer benign cysts with a smooth surface. Unfortunately, two months after treatment onset, one patient died of cardiac failure from doxorubicin toxicity, and one patient died from acute pericarditis-myocarditis from cyclophosphamide less than 3 weeks after treatment was started. One patient responded well to the first treatment course, but had a recurrence after 3 months, and died from pneumonitis. It is possible that an ill-advised treatment course with bleomycin may have contributed to her demise. One patient, a former heavy smoker aged 57 when her treatment began, died after 2 years and 11 months from a myocardial infarction. 5-fluorouracil treatment may also have contributed to her premature death. Another patient who responded poorly to the treatment nevertheless survived 2 years and 2 months, more than 2 years longer than she expected before she started the LSU treatment. The remaining 4 patients survived over 5 years without any sign of recurrence. 6. Prostate Cancers Six of the 8 prostate cancer patients in this study (of a total of >40), had extensive metastatic disease, one of them was dying, two needed assistance with walking, and 4 were given less than 6 months to live. All patients showed elevated levels of prostatic specific antigen (PSA) that ranged from 35 to 235 ng/mL at admission (Normal PSA < 4.0 ng/mL). In benign prostatic hypertrophy (BPH), PSA levels <25 ng/mL are seen. PSA is false negative in about 15% of the prostate cancers. The cutoff point for the disappearance of the cancer was set at 10 ng/mL. Very similar to the results in breast cancer patients, all palpable infiltrating tumor masses in all patients either disappeared or turned into benign, well-defined, cystic tumors of much smaller size. The dying patient succumbed to the side-effects of his chemotherapy 20 days after the beginning of his treatment. One of the severely debilitated patients died after 9 weeks also as a consequence of his chemotherapy. Two patients only partially responded to the treatment. One of these died in a horseback riding accident, the other died after 4 treatment courses 2 years and 5 months after he started the LSU cancer treatment. He had survived almost 2 years longer than was originally expected.
Four patients survived at least 5 years, two of them needed only one treatment course, one of them needed two, and the fourth needed four treatment courses. Their PSA levels were maintained below 10 ng/mL after their treatments were completed. 7. Colorectal Cancers Of the 6 patients in this study with colorectal cancers (of a total of >50), all had elevated values of carcinoembryonic antigen (CEA) in the range of 80 to 280 ng/mL, indicative of widespread metastatic disease; all of them had undergone surgical resections, 4 with colostomy, and 2 without colostomy. All 6 had received a full course of chemotherapy with 5-fluorouracil (5-FU) and a variety of other chemotherapeutics. Two of the patients received radiation therapy. The response of these patients to the LSU treatment program was not as impressive as for instance, in the case of liver cancer patients. Only the 2 patients without colostomy survived more than five years after 2 and 3 LSU treatment courses respectively. In both cases, the CEA was maintained below 5.0 ng/mL. One of the colostomy patients died from a heart attack after a good initial response to the treatment in the 11th week of his treatment. 5-FU-induced myocardial ischemia may have been a contributing factor. Another of the colostomy patients apparently died from a barbiturate overdose, possibly a suicide attempt. It should be noted that over 35 of the colostomy patients were lost in the follow-up. The two patients who had suffered abdominal radiation had severe problems with adhesions and fistulas. Both had severe diarrhea at admission that was controlled with diet within about 2 to 3 weeks. Though both had a life expectancy of less than 3 months at the time of admission, they survived for 2 years and 7 months, and 3 years and 3 months, respectively. Their CEA levels returned to below 5.0 ng/mL after 3 months and stayed there until their deaths. 8. Uterine Cervical Cancers All 6 patients in this study (of a total of>30) had undergone radical hysterectomies and pelvic lymphadenectomies, multiple radiation treatments, and full courses of chemotherapy (4 patients received a combination of doxorubicin and methotrexate; 4 patients received mitomycine, vincristine, and bleomycin; one patient had been given both combinations). One patient died after 2 years and 20 months after undergoing 4 courses of the LSU treatment. Originally she was given less than 3 months to live. One patient fell down a flight of stars, fractured her neck and died with hours. She had survived 3 years and 5 months. Her original life expectancy was less than one year. Two patients survived 5 years and had no indication of tumor recurrence on CAT scans and NMR imaging. For the normalization of abnormal Papanicolaou (PAP) smears [Group 2: Infections; Group 4: squamous cell CA; Group 5: adenocarcinoma; Group 6: nonepithelial malignancy] and even of Stage O (Carcinoma in situ) through Stage IA2 (strictly confined to cervix; depth: £5 mm, spread: £7 mm), cervical cancers, topical application of folic acid in conjunction with vaginal ozone application has been found virtually 100% effectivein about 30 patients. Vaginal ozone applications are also an effective prevention of cervical cancers since it removes HPV and other pathogens that are causing chronic cervicitis that may turn malignant. 9. Brain Cancers All 4 brain cancer patients (of a total of about 15) had highly malignant extensive glioblastomas. All 4 had undergone surgery and radiation, as well as glucocorticoid therapy. Two of the patients were unconscious at admission. The two conscious patients complained about headaches, especially in the morning, loss of appetite, nausea, loss of concentration, reduced mental capacity, and increased sleepiness. In both, personality changes were clearly evident.
After treatment onset both unconscious patients regained consciousness within 3 days and were able to say simple sentences within 5 and 8 days respectively. One of these patients suddenly deteriorated in the 4th week, possibly from malnutrition. His sister, who supervised his feeding, had failed to properly follow our instructions. When we found out that there was a problem, the patient was already beyond recovery. The other patient recovered well enough to return to his job as a real estate broker, and has survived 5 years without sign of recurrence. Both of the two conscious patients had a lethal car accident; one about 2-1/2 years, the other about 3-1/2 years after their treatments. Both accidents may have been related to personality and psychomotor changes caused by their original tumors. 10. Melanomas The three patients with melanoma in this study (of a total of about 12) all had widespread metastatic disease. They all responded well to the first course of treatment though less favorably to further treatment courses. One of the patients died after 11 months. She had originally been given less than one month to live. Another patient who had been given less than 6 months to live survived 2 years and 10 months. One of the patients, a black woman who had undergone 5 courses of treatment, survived 5 years without sign of malignancy. 11. Other Cancers The number of the 10 remaining tumors in this study (of a total remaining of >80), two ovarian cancers, two stomach cancers (one of which was combined with a pancreatic cancer; see under 4.), one osteosarcoma, one soft tissue sarcoma, two kidney cancers, one bladder cancer, and one adrenal cancer, is too small to allow any clear judgment of the effectiveness of the LSU treatment in these specific cancers. In all cases, a prompt response was seen in the first treatment course. One kidney cancer patient died after 20 days as a consequence of his chemotherapy. The other kidney cancer patient responded moderately well to the LSU treatment and died after 4 years and one month (well over 5 years after his original diagnosis & thus “cured” according to NCI statistics,). The stomach cancer patient who also had pancreas cancer is described above under 4. He died after 1 year and 3 months. The other-stomach cancer patient responded moderately well to consecutive LSU treatments and died after 4 years and 2 months (rather than after less than one year ; & would also be listed by NCI as “cured”). One ovarian cancer patient responded well and survived over 5 years. The other responded moderately well to consecutive LSU treatments and survived 3 years and 10 months.The bladder cancer patient did not respond well and died after 11-1/2 months (rather than after less than 1 month). The adrenal cancer did well, needed only one LSU treatment course, and survived over 5 years without sign of recurrence. Continued next page
The 200 Plus Cancers Treated from 1987 through 2003 The following are only general remarks since on 2 May 1992, U.S Government Agents simultaneously broke into three locations where the originals and two copies of some 3000 patient records treated by LSU from 1980 through 1992, including about 650 cancer patients, about 180 AIDS patients, about 80 multiple sclerosis patients, and over 2000 patients with different conditions that were the data basis for the 2d ed. of the Ozone Book that for reasons beyond the control of the authors took until the year 2004 to be finally completed. . Again, we see a prevalence of “incurable” cancers (a) which have 0.0% success rate and thus should NOT be treated conventionally at all, including, small cell lung, pancreas, & esophagus cancers, acute adult leukemias, and all cancers with widespread metastasis; (b) malignancies where conventional treatment in almost all cases shortens the life span, including, stomach, brain, liver, & most ovarian cancers, multiple myeloma & chronic adult leukemias, as well as large (>10 cm = >2″) fast growing cancers with lymph node metastasis; (c) cancers with the highest incidence (in the USA & Western Europe), including, (female) breast, prostate, lungs[see (a)], & colon, where with early detection there is about 50% 5-year survival in breast, of 60% in prostate, & about 25% in colon cancers, that drops precipitously to some 10% if (b) & 1.0% if (a), supra, conditions are present; (d) other cancers including non-Hodgkin lymphomas, cancers of the urinary bladder & kidneys, rectum, (epi/naso)pharynx & oral cavity, endometrium & uterine cervix, & melanomas of the skin, rectovaginal cancer, larynx & thyroid cancer, Ewing sarcoma, etc. [which includes all 20 most frequent cancers in Thailand]. The estimated overall 5-year survival rate of all of these cancer patients, almost all of them terminal with widespread metastasis [see (a)] & [seeking our treatment only] after all conventional treatments had been exhausted, was ~40%, which increased to ~50% if they survived the first 3 weeks after treatment onset, & to ~60% if they survived 3 months after treatment onset, even more, ~80%, if they had a chance to have follow-up treatments at LSU, which was denied to virtually all patients after 17 July 1998 & until mid-2003, and many of which would be alive today; and while the estimated 5 year survival of untreated [with conventional methods: surgery &/or radiation &/or chemotherapy, etc.] patients was about 95% if they kept in touch with LSU/ULS, had a purpose to their lives with goals they absolutely needed to achieve, no matter what, meticulously maintained their alkalinizing blood-type-specific supplementation/diet/lifestyle, & balanced mind/ body/spirit as practitioners of Taoist Energy Healing, Silva Mind Control, & Neurolinguistic Programming (NLP).
Why is it essential that you stay in touch with us after completion of your initial treatment? Because we will use EVERY METHOD AVAILABLE to get & keep you well These methods, individually tailored to your specific needs, may include but are not limited to the following:
1. Herbal Electron Donors & Propagermanium (both for treatment & maintenance): The most effective herbal electron donors that restore the body to an alkaline balance can be found in plants containing high amounts of germanium (Ge). Medicinal plants that reputedly have anticancer activity and that contain high amounts of Ge include shelf fungus (Trametes cinnabarina; 800- 2000 ppm), Ginseng (Panax ginseng; 250-350 Korean < 4000ppm), garlic (Allium sativum; 750 ppm), d?ng-sh?n/sansukon root (Codonopsis pilosula; 260 ppm), sushi (Angelica pubescens; 260 ppm), Bandai moss (260 ppm), Japanese waternut (Trapa japonica: 240 ppm), Comfrey (Symphytum officinale; 150 ppm), boxthorn seed (Lycium chinense; 125 ppm), wisteria knob/gall (Wisteria floribunda; 110 ppm), pearl barley (fructus coicis lacryma-jobi; 75 ppm), etc. Based on this concept, Kazuhiko Asai synthesized numerous non-toxic Ge compounds, most notably, propagermanium or biscarboxyethyl Ge sesquioxide [O3(Ge.CH2.CH2.COOH)2], which has been found effective in the prevention and treatment of numerous cancers and their metastases including cancers of the lungs, prostate, breast, liver, kidney, brain tumors, lymphomas and leukemias, and sarcomas such as chondro- and osteosarcomas. The recommended dosage for prevention is 100 to 200 mg/day and for treatment 1000 to 4000 mg/day for a 60 kg patient. Except for a Herxheimer-type “healing crisis” reaction, no other adverse effects have been observed with this compound. If no effect is seen, the treatment should be discontinued after 60 days.
2. Other Proven Effective Herbal Combinations: Herbal treatments of cancer which were used worldwide since time immemorial include: Shark cartilage, Resistocell®, the thymus preparations Thymex L® and TFZ-Thymomodulin®, colostrum-derived transfer factor (TF) according to H. Hugh Fudenberg, Dr. Nieper¹s natural anticancer substances, and herbal cancer treatments such as compounded Hoksey [Trifolium pratense, Rhammus cathartica, Berberis vulgaris, Arctium lappa, Stillingia sylvatica, Rhammus purshiana or Cascara amarga (Sweetia panamensis), Glycyrrhiza glabra, Zanthoxylum clava-herculis], compounded Echinacea [Echinacea spp, Ceanothus americanus, Baptisia tinctoria, Thuja occidentalis, Stillingia sylvatica, Iris versicolor, Zanthoxylum clava-herculis], Folia Thujae occidentalis (fresh), Radix Astragali membranacei (Huáng Qí), Radix Rumicis crispi (fresh), and Renèe Caisse’s Essiac compound [Rumex acetosella, Arctium lappa (fresh root), Ulmus rubra, Rheum palmatum (root), etc.], PDR Cancer Formula [Larrea divaricata (folia), Sanguinaria canadensis (radix), Trifolium pratense (flores), Arcticum lappa (radix); Echinacea purpurea (radix), Hydrastis canadensis (radix); Symphytum officinale (folia), Eleutherococcus senticosus (radix; eventually folia, radix, and flores), Chelidonium maius, combined with Artemisia absinthium, Yucca spp, and Commiphora molmol (gum), C. abyssinica (myrrh), or C. opobalsamum (bdellium-oleoresin)], Laetrile® et al. mandelonitriles, immunostimulating mushroom extracts from Grifola frondosa (maitake), Ganoderma lucidum (reishi), and Lentinusedodes (shiitake), combined with herbs for specific cancers; e.g., herba Hedyotis diffusae (bái hu? shé c?o) combined with herba Scutellariae barbatae (bàn zh? lían) for stomach, esophageal, & colon cancers , & the latter alone for lung cancers, & tuber Dioscoreae bulbiferae (huáng yào z?) for thyroid cancer & endemic goiter, and, especially, Haelan 851® Platinum Formula and Natures Blessing.
3. WILL TO LIVE – MENTAL RECONDITIONING: What virtually all cancer survivors, particularly the ones that had been undergoing conventional therapies, have in common is that they had a purpose to their lives with goals they absolutely needed to achieve, no matter what. If counseling is successful in restructuring an individual’s outlook on life along those lines considerable life extensions beyond all expectations can be achieved after conventional therapies, while with the enhanced high pH therapy, the success is virtually guaranteed, provided that the patient has survived the first three months after the treatment started, and that they followed the programs outlined under 4. Conventional cancer treatment attempts, particularly surgery, that may in many cases frustrate all efforts to restore the will to live include colostomies, crippling lung resections, amputations of limbs, especially in children, cosmetically poor results after head, neck, & breast surgery &/or radiation. The same applies to paralysis after collapse of vertebrae from metastasis or from brain malignancies. Continued next page
4. DIET & LIFESTYLE: Meticulously maintaining their prescribed alkalinizing blood type specific diet, supplementation, exercise program, and lifestyle is as essential as mental reconditioning [see 3.] and energy balancing [see 5.]. Individualized supplementation may include maintenance doses of cesium & rubidium, potassium & magnesium salts, Wobemugos, bromelain, papain, superoxide dismutase (SOD), & other enzymes, coenzyme Q10, vitamin A & beta-carotene, selenium & vitamin E, vitamin C, quercetin, & isoflavones, lycopene, N-acetyl cystein (NAC), pycnogenol, d-limonene, curcumin, alpha lipoic acid, inositol, methylsulfonylmethane (MSM), ellagic acid & graviola (Annona muricata), Primal Defense, Nature’s Blessing, green tea, olive leaf extract, echinacea, garlic, parsley, Korean ginseng, apricot pits, wheat grass, chlorella, cod & shark liver oils, contortrostatin, carrot & cabbage juices, mogu (Kompucha) tea, regular escargots & soy bean products for blood type As & ABs, and over 20 other cancer fighting foods according to your blood type & individually tailored to specific needs. The blood type specific diet & exercise program follows largely the one outlined in Dr. Peter J. D’Adamo’s book “Live Right Four Your Type”, modified & amplified based on our own research including avoidance of sugar & fructose ( & all refined carbohydrates) by all types, particularly Os & Bs, avoidance of cow’s milk, particularly Os & As, avoidance of the foods shown harmful for all types including pork, etc. All these programs have been streamlined and are available through people I have trained and shown a dedication to the ongoing development of High PH Therapy. With the most well structured program being available through Paul Rana of The RANA System in Australia, Dr Pablo at XYZ-Wellbeing Retreat Facility and Dr Sherrie in India.
____________________________________
Abdul-Haqq H.E. Sartori, M.D
Page 4 of 5
Prof. Abdul-Haqq Sartori, M.D. Medicina Alternativa Professor of Alternative Medicines
RE: Enhanced High-pH Therapy for Cancer now available through trained Practitioner at XYZ Wellbeing ReTreat Facility founded in the year 2000 and undergoing a major refit and expansion in late 2008.
Thank you for contacting me to enquire about Cesium chloride (CsCl) and the Enhanced High-pH Therapy for Cancer originated by A. Keith Brewer, Ph.D., and since 1980 enhanced and perfected by myself.
Though the results were published in a major peer-reviewed medical journal, Pharmacology, Biochemistry, and Behavior in the December 1984 Supplement I, there was, except for the late Dr. Hans Nieper, a minimum of response from both the orthodox and alternative medical community.
Therefore, unfortunately, I am the only physician left who uses this by far most consistently effective therapy for all fast-growing cancers that have been treated so far, no matter what stage or type or extent. So as I am aging, I have trained a few people the correct and safe way to use this therapy. Do not be experimented on, my many years of research are beyond reproach.
Please read all my notes before you undertake any program. Since 1980, over 700 cancer patients have been treated with this therapy. In all cases, fast-growing tumors were promptly reduced in size with minimum discomfort to the patient (as compared to the common and sometimes horrendous adverse effects of chemotherapy and after radiation). With the intravenous (I.V.) application of this therapy, we consistently achieved primary & metastatic tumor reductions of 1.0 to 2.0 cm (2/5 to 2/5 of an inch) per day, i.e., disappearance of 5.0 cm (2.0) tumors in about four days, and of 10.0 cm (4.0) tumors in about eight days, and reductions of lymph node metastases of 2-5 mm/day.
Besides the higher and more consistent effectiveness, I.V. application of CsCl and other minerals, vitamins, mandelonitriles (e.g., Laetrile®), etc., avoids all side effects from oral therapy such as nausea, vomiting, diarrhea, abdominal discomfort, etc. Furthermore, I.V. application guarantees that all ingredients are taken up by the body, as often nutrient absorption may be compromised, particularly in patients with any type of malabsorption from gastrointestinal problems or in many advanced cancers or simply from lack of hydrochloric acid.
The only side effects seen with this therapy is the sometimes considerable, but brief, discomfort from the I.V. application of Ozone that is, in fact, a most beneficial homeopathic-type healing crisis. Best of all, this healing crisis reverses virtually all tendencies towards any type of illness and, in due time, almost all patients report that have “never felt better” in their entire life. In a tireless effort, Paul Rana, since 1998, developed most effective and comprehensive system in preparation for and as follow up of the Enhanced High pH Therapy.
The Rana System is an integral part of our therapy and you should follow it for at least one year or, preferably, for the rest of your life. Following this System gives you not only the highest success rates in permanently overcoming cancer but also greatly enhances your overall health, happiness, vigor, and longevity. For more information about The RANA SYSTEM and how to become a member, please consult with Paul Rana or peruse his websites in Australia.
I have passed on The RANA System research papers and system manuals with permission to www.xyz-wellbeing.com team 1995, early results are exciting to say the very least and the upgrade of a ReTreat Facility in Colombia is scheduled in 2008. Contact Dr Pablo at xyz for details.The Enhanced High-pH Therapy for cancer within the framework of The XYZ Wellbeing ReTreat System is now available in Colombia at a fraction of the financial costs of any conventional therapy that, besides very poor results in most cancers, causes severe suffering and in many cases permanent damages, and is the main cause for premature deaths in cancer patients. Since 1970, the start of President Nixon’s War on Cancer, the yearly death rate in the U.S.A. went up from 135,000 to over 800,000 and the average cost per patient is around US$ 300,000.00 ($ 100,000 to over $ 1,000,000.00) with an average out of pocket expenses for insured patients of about $ 60,000.00 ($ 20k to >200k).
Compared with this, the total all-inclusive investment for six to nine weeks of treatment in Colombia including the Enhanced High-pH Therapy for cancer (with room & board for a companion) and ongoing follow-up, as well as setup & three months of all supplements. They have designed a three month in house and 3 month follow up program that is under research that includes the best combination of services and the most determined team I have seen. If you are one of those patients that seek us out first when their primary tumor is less than 5.0 cm (2.0″) in diameter (and which have not yet undergone any conventional treatment), they should offer you a special price.
Also enclosed are my letters o
Article from articlesbase.com
Datamonitor forecasts the inflammatory bowel disease market to become increasingly competitive with the anticipated launch of seven new products, spanning five drug classes from 2010 to 2019. These therapies are forecast to inject over billion into a market projected to reach up to .7 billion by 2019 and offer more therapy choice to specific patient groups.
Scope
*Segmentation and analysis of products across all stages of the IBD pipeline with in-depth discussion of key Phase II and III pipeline therapies
*Insight and analysis of market potential including robust epidemiology forecasts, and a review of key opinion leader requirements for new products
*Ten-year indication-specific forecasts of seven pipeline products, with a comparison of their relative clinical and commercial attractiveness
*Review of unmet needs based on key opinion leader interviews and a focus on innovative early-stage drug development and assessment of future treatment
Highlights
Datamonitor identified 108 products across all stages of development, but these treatments vary immensely by target. The diversity of the pipeline will broaden future therapy choice for specific patient groups, such as TNF-failure patients and the mild to moderate group.
Opinion leaders cite the re-randomization of patients responding to initial treatment in Crohn’s disease trials as an effective design. In ulcerative colitis assessing induction and maintenance treatment in separate studies of new drugs will play a significant role in drug labeling, particularly for the European Medicines Agency.
Two key late-stage pipeline drugs show particular clinical and commercial potential. Simponi (golimumab) is viewed positively by opinion leaders for ulcerative colitis. In Crohn’s disease, chemokine antagonist GSK1605786 (Traficet-EN) is anticipated to reach the market by 2017 and could potentially threaten biologics as a maintenance agent.
Reasons to Purchase
*Understand the recent advances in the inflammatory bowel disease pipeline and gain insight into leading gastroenterologist opinion
*Access sales forecasts for late-stage pipeline products and understand new product positioning through analysis of clinical and commercial factors
*Evaluate the unmet needs in both Crohn’s disease and ulcerative colitis and the challenges faced in clinical trial development
Overview 1
Catalyst 1
Summary 1
About Datamonitor Healthcare 2
About the Immunology & Inflammation pharmaceutical analysis team 2
Executive Summary 3
Strategic scoping and focus 3
Datamonitor insight into the disease market 3
Related reports 5
Upcoming related reports 5
Table of Contents 6
1. Pipeline Overview and Dynamics 7
Key findings 7
Pipeline overview 8
Diverse late-stage pipeline for inflammatory bowel disease 8
Companies remain interested in inflammatory bowel disease, particularly ulcerative colitis 10
Limited number of candidates have made it to Phase III 11
Interleukin and TNF inhibitors are most commonly targeted, while development focuses on oral delivery 12
Comparative forecasts 14
Datamonitor pipeline assessment summary 16
Key companies involved in the inflammatory bowel disease pipeline 17
Centocor Ortho Biotech 17
Cosmo Pharmaceuticals 18
GlaxoSmithKline 18
2. Epidemiology 20
Key findings 20
Definition 21
Crohn’s disease 21
Ulcerative colitis 21
ICD-10 codes used to define the inflammatory bowel disease indications 21
Patient segmentation by anatomical location 22
Ulcerative colitis 23
Crohn’s disease 23
Patient segmentation according to disease severity 25
Crohn’s disease 25
Mild-to-moderate Crohn’s disease 25
Moderate-to-severe Crohn’s disease 25
Fistulizing Crohn’s disease 25
Severe fulminant Crohn’s disease 26
Remission in Crohn’s disease 26
Ulcerative colitis 26
Mild ulcerative colitis 26
Moderate ulcerative colitis 26
Severe ulcerative colitis 26
Fulminant ulcerative colitis 27
Remission 27
Segmentation of patients by severity useful for directing therapy, but is not clearcut 28
Disease definition and diagnosis criteria used in epidemiology analysis 28
Crohn’s disease 29
Ulcerative colitis 29
Global variation and historical trends 30
Risk factors 33
Genetics 33
Environmental factors 34
Smoking 34
Epidemiologic forecasting of IBD 35
Sources of epidemiologic data 35
Description of methods 35
Japan 36
US 36
European markets 36
Epidemiological results 38
Current prevalent cases and future trends of Crohn’s disease 38
Current prevalent cases and future trends of ulcerative colitis 41
Discussion 44
Strengths of Datamonitor’s epidemiologic projections 45
Conclusions 45
Rest of the world 46
3. Current Market Overview 47
Key Findings 47
Current treatment options 48
Topical and oral 5-aminosalicylates (5-ASAs) 48
Corticosteroids 49
Immunomodulators 49
Biologics 50
Antibiotics 50
Antidiarrheal and fluid replacement 50
Leading treatments for inflammatory bowel disease 50
Current gold standard and comparator therapies 52
5-aminosalicylates remain the gold-standard therapy in ulcerative colitis 52
Gold-standard in Crohn’s disease is less clearcut 53
Comparator drug 54
Remicade (infliximab) is the comparator therapy in both Crohn’s disease and ulcerative colitis 54
Current market overview 55
Unmet needs in Crohn’s disease and ulcerative colitis 58
Crohn’s disease 58
Effective agents for maintaining remission without immunosuppression 58
Drugs needed for mild Crohn’s disease population 59
Safer oral therapies as an alternative to expensive biologics 59
Effective treatments for fistulizing Crohn’s disease 59
Predicting response to therapy 60
Better activity measurements in clinical trials 60
Ulcerative colitis 61
Powerful, well-tolerated agents for inducing remission quickly and an oral maintenance agent are most wanted 61
Drug therapies for refractory patient population 61
Disease-modifying drugs 62
Simple blood test to indicate disease activity 62
Target product profile versus current level of attainment 62
Efficacy 64
Crohn’s disease 64
Ulcerative colitis 65
Safety 66
Formulation 66
Cost 67
4. R&D Approach 68
Key findings 68
Clinical trial design in Crohn’s disease 69
Changes in inflammatory bowel disease clinical trial design have been two-fold over the last decade 69
Crohn’s disease trial design remains a work in progress, but aided by several recently published guidelines 70
Indices that reflect inflammation are needed in modern Crohn’s disease trial design 72
Time point to assess the effectiveness of drugs in clinical trials 72
Randomization of patients from onset of trial with induction and maintenance endpoint deemed less effective 73
ACT, PRECiSE-2 and CHARM trials set a precedent for modern Phase III Crohn’s disease trials 74
Clinical trial design in ulcerative colitis 75
Ulcerative colitis clinical development guidelines for European approval 75
Indices in clinical trials of ulcerative colitis 76
Remicade’s ACT clinical trial set the precedent for modern ulcerative colitis trial design 76
5. Pipeline Analysis & Forecasts: TNF inhibitors 78
Key findings 78
Overview for TNF inhibitors 79
Pipeline summary 79
Simponi (golimumab; Centocor Ortho Biotech/Merck & Co./Mitsubishi Tanabe) 79
Drug overview 79
Drug profile 80
Clinical trial data 80
SWOT analysis 82
Datamonitor drug assessment summary for Simponi 83
Clinical and commercial attractiveness 85
Potential to switch patients from Remicade to Simponi 85
Simponi targets only the moderate to severe ulcerative colitis subgroup 87
Company experience boosts commercial attractiveness, but arbitration between Johnson & Johnson and Schering-Plough is concerning 87
Satisfaction of unmet needs 87
Forecasts to 2019 89
TNF-kinoid (debio0512; Neovacs) 91
Key early-stage and preclinical compounds in TNF inhibitors 91
6. Pipeline Analysis & Forecasts: Corticosteroids 93
Key findings 93
Overview for corticosteroids 94
Pipeline summary 94
Budesonide MMX (Cosmo/Ferring/Santarus) 94
Drug overview 94
Drug profile 95
Clinical trial data 95
Phase III studies 95
SWOT analysis 98
Datamonitor drug assessment summary for Budesonide MMX 99
Clinical and commercial attractiveness 101
MMX delivery system sets Budesonide MMX apart from other corticosteroids 101
Potential for Budesonide MMX as first-line ulcerative colitis therapy, but more data needed 103
Commercial potential for Budesonide MMX in the European market 103
Satisfaction of unmet needs 104
Forecasts to 2019 105
Other drugs in the corticosteroid class 108
COLAL-PRED (prednisolone sodium metasulfobenzoate) 108
Key preclinical compound in corticosteroids 110
7. Pipeline Analysis & Forecasts: Integrin inhibitors 111
Key findings 111
Overview for integrin inhibitors 112
Pipeline summary 112
Comparative forecasts 112
Vedolizumab (MLN0002; (Takeda/Millennium Pharmaceuticals) 114
Drug overview 114
Drug profile 114
Clinical trial data 115
Phase III studies: GEMINI studies 115
SWOT analysis 118
Datamonitor drug assessment summary for vedolizumab 118
Clinical and commercial attractiveness 120
Targeting both Crohn’s disease and ulcerative colitis boosts patient potential 120
Safety profile negatively impacts on clinical attractiveness 122
Takeda has available resources, but lacks experience in inflammatory bowel disease 122
Satisfaction of unmet needs 122
Forecasts to 2019 125
AJM300 (Ajinomoto) 128
Drug overview 128
Drug profile 128
Clinical trial data 128
SWOT analysis 130
Datamonitor drug assessment summary for AJM300 130
Clinical and commercial attractiveness 132
Large patient potential as both Crohn’s disease and ulcerative colitis are targeted 132
Ajinomoto gaining inflammatory bowel disease market experience 134
Satisfaction of unmet needs 134
Forecasts to 2019 136
Key early-stage and preclinical compounds in integrin inhibitors 138
8. Pipeline Analysis & Forecasts: Other cytokine targets 139
Key findings 139
Overview for cytokine targets 140
Pipeline summary 140
Comparative forecasts 140
Stelara (ustekinumab; Centocor Ortho Biotech/Janssen-Cilag) 142
Drug overview 142
Drug profile 142
Clinical trial data 143
SWOT analysis 145
Datamonitor drug assessment summary for Stelara (ustekinumab) 146
Clinical and commercial attractiveness 148
Formulation strategy remains unclear 148
Potential for ustekinumab in anti-TNF failure or biologics setting 149
Company experience in the autoimmune area 149
Satisfaction of unmet needs 150
Forecasts to 2019 151
GSK1605786 (formerly Traficet-EN, CCX282; ChemoCentryx/GlaxoSmithKline) 153
Drug overview 153
Drug profile 154
Clinical data 154
PROTECT-1: maintenance phase of trial shows positive data 155
PROTECT-1: induction phase of study 157
Phase II trial data 159
SWOT analysis 159
Datamonitor drug assessment summary for GSK1605786 (Traficet-EN) 160
Clinical and commercial attractiveness 162
Positive Phase II/III shows more definitive data on remission but dosing issues need to be resolved 162
Commercial potential boosted by GlaxoSmithKline’s resources, but the company lacks IBD experience 164
First-in-class for Crohn’s disease as an alternative to immunosuppressants 164
ChemoCentryx is also developing CCX025, a potential back-up to GSK1605786 164
Potential for future indication expansion into ulcerative colitis 164
Satisfaction of unmet needs 164
Forecasts to 2019 165
ABT-874 (briakinumab; Abbott) 167
AIN457 (Novartis) 169
AG011 (ActoGeniX) 169
STA5326 (apilimod mesylate; Synta Pharmaceuticals) 170
MDX-1100 (Bristol Myers Squibb) 170
Late-stage development compounds recently discontinued 171
Simulect (Basiliximab BSX; Cerimon Pharmaceuticals) 171
Rebif (interferon-beta-1a; Merck Serono) 171
Key early-stage and preclinical compounds in other cytokine targets 172
9. Pipeline Analysis & Forecasts: Others 173
Key findings 173
Overview for other drugs 173
Pipeline summary 173
LMW Heparin MMX (CB-01-05-MMX, parnaparin sodium; Cosmo Pharmaceuticals) 175
Drug overview 175
Drug profile 176
Clinical trial data 176
SWOT analysis 178
Datamonitor drug assessment summary for LMW Heparin MMX 179
Clinical and commercial attractiveness 181
Large patient potential as LMW Heparin MMX targets mild-to-moderate ulcerative colitis 181
Cosmo has some market experience in ulcerative colitis 182
Promising initial clinical data support clinical attractiveness 182
Satisfaction of unmet needs 182
Forecasts to 2019 184
Prochymal (Osiris Therapeutics/Genzyme) 185
Drug overview 185
Drug profile 186
Clinical trial data 186
Phase III Crohn’s disease study enrollment discontinued, but strong partnership with Genzyme 188
Alicaforsen sodium (AP1431, AP1451, AP1007; Atlantic Healthcare) 189
Drug overview 189
Clinical data 190
Other drugs 190
Tasocitinib (CP-690550; Pfizer) 190
Tetomilast (OPC6535; Otsuka Pharmaceuticals) 193
LT-02 (Lipid Therapeutics) 194
HMPL004 (Hutchison MediPharma) 195
Dersalazine sodium (UR-12715; Palau Pharma) 196
Late-stage development compounds recently discontinued 196
Orencia (abatacept; Bristol-Myers Squibb) 196
Drug overview 196
Drug profile 197
Clinical trial data 197
Phase III Crohn’s disease study 197
Phase III ulcerative colitis study 200
Clinical program of abatacept for inflammatory bowel disease comes to an end 202
Visilizumab (HuM291; PDL BioPharma) 202
Key early-stage compounds in others 203
10. Innovative Early-Stage Approaches 206
Key findings 206
Overview of early-stage innovative projects 207
Toll-like receptors- promising preclinical target 207
Interleukin 6 – preclinical models suggest potential in inflammatory bowel disease 208
Targeting IL-6 five or more years away in inflammatory bowel disease 210
Interleukin 10 -potential target for inflammatory bowel disease 211
Early-stage inflammatory bowel disease pipeline is diverse 211
The future of treatment in inflammatory bowel disease 211
Bibliography 214
Journals 214
Websites 224
Datamonitor reports 230
APPENDIX 231
Methodology 231
Datamonitor forecast methodology 231
Product forecasts 231
Derivation of sales forecasts and pricing trends 231
Exchange rates 231
Definition of a standard unit 232
Datamonitor drug assessment scorecard 232
Contributing experts 233
About Datamonitor 234
About Datamonitor Healthcare 234
About the Disease analysis team 234
Datamonitor consulting 235
Disclaimer 237
ReportsandReports, comprising of an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. ReportsandReports announce to have Research Report on Pipeline Insight: Inflammatory Bowel Disease – Varied drug targets to broaden future therapy options Market Research Report in its store. Browse all our Market Research Reports details at ReportsandReports.com
Article from articlesbase.com
Related Ms Disease Articles
MS Learn Online is the National MS Society’s online educational webcast series. This video features country music star Clay Walker, who talks about the importance of people with multiple sclerosis to get on a disease modifying therapy.
